The 10-second takeaway
For the quarter ended March 31 (Q1), Cynosure beat expectations on both revenue and earnings per share.
Compared to the prior-year quarter, both revenue and GAAP earnings per share increased. The profit was a surprise, as analysts had predicted a loss.
Margins expanded across the board.
Cynosure logged revenue of $34.2 million. The three analysts polled by S&P Capital IQ wanted to see sales of $31.7 million on the same basis. GAAP-reported sales were 56% higher than the prior-year quarter's $21.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.06. The four earnings estimates compiled by S&P Capital IQ averaged -$0.02 per share. GAAP EPS were $0.06 for Q1 against -$0.15 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 57.1%, 100 basis points better than the prior-year quarter. Operating margin was 2.5%, 1,010 basis points better than the prior-year quarter. Net margin was 2.4%, 1,110 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $35.8 million. On the bottom line, the average EPS estimate is $0.08.
Next year's average estimate for revenue is $137.6 million. The average EPS estimate is $0.30.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 368 members rating the stock outperform and 13 members rating it underperform. Among 93 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 88 give Cynosure a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cynosure is buy, with an average price target of $22.20.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Cynosure performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add Cynosure to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.